Telpil-M 25 Tablet ER
Marketer
Psychotropics India Ltd
Salt Composition
Telmisartan (40mg) + Metoprolol Succinate (25mg)
Overview Telpil-M 25 Tablet ER
Telpil-M 25 Extended-Release tablets manage hypertension, reducing the risk of cardiovascular events like strokes and heart attacks. Early use significantly improves heart attack survival rates. For consistent blood levels, take this medication with food daily at the same time, as directed by your physician. Continued use is crucial, even if feeling well, as hypertension is often asymptomatic; premature discontinuation can worsen the condition. Lifestyle modifications, including regular exercise, weight management, and a balanced diet, further enhance blood pressure control. Adhere strictly to your doctor's instructions. Possible side effects include headache, weakness, dizziness, low blood pressure, elevated potassium levels, occasional orthostatic hypotension (possibly with fainting), shortness of breath, nausea, vomiting, abdominal discomfort, and tiredness. Avoid potassium-rich foods and supplements. Dizziness may occur; avoid driving and rise slowly from a seated position. Regular monitoring of blood pressure, blood sugar, kidney function, urea, and electrolytes may be required. Inform your doctor about any pre-existing liver or kidney conditions, and pregnant or breastfeeding individuals should seek medical advice before use. Always disclose all medications, particularly those for hypertension or heart disease.
Uses of Telpil-M 25 Tablet ER
Managing Elevated Blood Pressure
Major Benefits of Telpil-M 25 Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for Telpil-M 25 Tablet ER. Ingest the tablet whole; avoid crushing, chewing, or breaking it. Administer this medication with a meal.
Common Side effects of Telpil-M 25 Tablet ER:
- Headache
- Weakness
- Dizziness
- Cold extremities
- Slow heart rate
- Increased potassium level in blood
- Decreased blood pressure
- Orthostatic hypotension (sudden lowering of blood pressure on standing)
- Breathlessness
- Vomiting
- Abdominal pain
How to use Telpil-M 25 Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Telpil-M 25 Tablet ER whole; avoid crushing, chewing, or breaking it. Administer this extended-release tablet with a meal.
How Telpil-M 25 Tablet ER works:
Telmisartan and Metoprolol Succinate, combined as Telpil-M 25 ER tablets, offer a dual-action approach to blood pressure management.
SAFETY ADVICE
AlcoholUNSAFE
Combining Telpil-M 25 Tablet ER and alcohol is inadvisable due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
Extended-release Telpil-M 25mg tablets present a confirmed risk to a fetus; therefore, their use during pregnancy is contraindicated. In exceptional, life-threatening circumstances, a physician might prescribe them if the potential advantages outweigh the known dangers. Physician consultation is essential.
Breast feedingSAFE IF PRESCRIBED
Extended-release Telpil-M 25 mg tablets are likely safe for use while breastfeeding. Available human data indicates minimal risk to the infant.
DrivingUNSAFE
Extended-release Telpil-M 25mg tablets can cause drowsiness, blurred vision, and dizziness. Refrain from driving if you experience these effects.
KidneySAFE IF PRESCRIBED
Extended-release Telpil-M 25mg tablets are considered safe for use in individuals with impaired renal function. No alteration of the Telpil-M 25mg ER dosage is necessary.
LiverCAUTION
Extended-release Telpil-M 25 mg tablets require careful administration for individuals with hepatic impairment. Dosage modification may be necessary. Physician consultation is recommended.
What if you forget to take Telpil-M 25 Tablet ER :
Should you forget a Telpil-M 25 Tablet ER dose, take it immediately. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Telpil-M 25 Tablet ER
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Therapy | HEART |




